Pre-treatment of hyponatremia as a biomarker for poor immune prognosis in advanced or metastatic gastric cancer: A retrospective case analysis
Hyponatremia, a prevalent electrolyte imbalance among tumor patients, has often been overlooked regarding its prognostic significance for immunotherapy. In this study, we delved into the prognostic ramifications of hyponatremia in advanced gastric cancer (AGC) patients undergoing immunotherapy. Enro...
Gespeichert in:
| Veröffentlicht in: | Human vaccines & immunotherapeutics 2024-12, Vol.20 (1), p.2414546 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 2414546 |
| container_title | Human vaccines & immunotherapeutics |
| container_volume | 20 |
| creator | Pan, Yuting Ma, Yue Guan, Huafang Dai, Guanghai |
| description | Hyponatremia, a prevalent electrolyte imbalance among tumor patients, has often been overlooked regarding its prognostic significance for immunotherapy. In this study, we delved into the prognostic ramifications of hyponatremia in advanced gastric cancer (AGC) patients undergoing immunotherapy. Enrolling AGC patients diagnosed between December 2014 and May 2021, we extracted pertinent data from electronic medical records, with a median follow-up of 35.8 months. Kaplan-Meier curves illuminated patients' progression-free survival (PFS) and overall survival (OS), while survival disparities were tested using the Mantel-Haenszel log rank test. COX and logistic regressions were employed to scrutinize the correlation between serum sodium levels and prognosis in 268 AGC patients, both at baseline and during treatment. Notably, patients with hyponatremia exhibited shorter PFS (4.7 vs 2.1 months, p = .001*) and OS (12.5 vs 3.9 months, p |
| doi_str_mv | 10.1080/21645515.2024.2414546 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_21645515_2024_2414546</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a5295c601de442538dc22945e42c3ca4</doaj_id><sourcerecordid>3117078983</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-4b61459c02b1b264935a791abca5de88687122c2b44fb3a0c8e9e05b060c54c63</originalsourceid><addsrcrecordid>eNp9Uk1v1DAQjRCIVqU_AeQjl2xtx84HF6gqKJUqwQEkbtbEmWxdkjjY3q32T_CbmbDbFb3ggz2aefPmwy_LXgu-ErzmF1KUSmuhV5JLtZJKKK3KZ9np4s-1Vj-eH22hT7LzGO85nYrQZfkyOykaJUQjm9Ps99eAeQoIacQpMd-zu93sJyDX6IBBZMBa50cIPzGw3gc2e7rcOG4mZHPw68lHF5mbGHRbmCx2jOIjJogJkrNsTUag1y7B8I5dsoAp-DijTW6L5I_IYIJhRzyvshc9DBHPD-9Z9v3Tx29Xn_PbL9c3V5e3uVWiSLlqSxq5sVy2opWlagoNVSOgtaA7rOuyroSUVrZK9W0B3NbYINctL7nVypbFWXaz5-083Js5OBpwZzw489fhw9pAoO4HNKBlo23JRYdKSV3UnZWyURqVtIUFRVzv91zzph2xs7THAMMT0qeRyd2Ztd8aIVRNcwhieHtgCP7XBmMyo4sWhwEm9JtoCiEqXtVNXRBU76GWVhgD9sc6gptFG-ZRG2bRhjlog_Le_NvkMetRCQT4sAe4iX55hAcfhs4k2A0-9IH-zi19_LfGHwFByv0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3117078983</pqid></control><display><type>article</type><title>Pre-treatment of hyponatremia as a biomarker for poor immune prognosis in advanced or metastatic gastric cancer: A retrospective case analysis</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Alma/SFX Local Collection</source><creator>Pan, Yuting ; Ma, Yue ; Guan, Huafang ; Dai, Guanghai</creator><creatorcontrib>Pan, Yuting ; Ma, Yue ; Guan, Huafang ; Dai, Guanghai</creatorcontrib><description>Hyponatremia, a prevalent electrolyte imbalance among tumor patients, has often been overlooked regarding its prognostic significance for immunotherapy. In this study, we delved into the prognostic ramifications of hyponatremia in advanced gastric cancer (AGC) patients undergoing immunotherapy. Enrolling AGC patients diagnosed between December 2014 and May 2021, we extracted pertinent data from electronic medical records, with a median follow-up of 35.8 months. Kaplan-Meier curves illuminated patients' progression-free survival (PFS) and overall survival (OS), while survival disparities were tested using the Mantel-Haenszel log rank test. COX and logistic regressions were employed to scrutinize the correlation between serum sodium levels and prognosis in 268 AGC patients, both at baseline and during treatment. Notably, patients with hyponatremia exhibited shorter PFS (4.7 vs 2.1 months, p = .001*) and OS (12.5 vs 3.9 months, p < .001*). Serum sodium emerged as an independent prognostic factor for both PFS (HR = 1.773; 95% CI 1.067-2.945; p = .001*) and OS (HR = 1.773; 95% CI 1.067-2.945; p = .003*). Subgroup analysis revealed that AGC patients with hyponatremia derived no benefit from immunotherapy in terms of PFS and OS. Strikingly, a decrease in serum sodium during immunotherapy was associated with early relapse and mortality. Based on these findings, we hypothesize that hyponatremia portends poor prognostic outcomes in AGC patients treated with immunotherapy and may serve as a valuable prognostic biomarker. However, further large-scale prospective studies are warranted to validate these observations.</description><identifier>ISSN: 2164-5515</identifier><identifier>ISSN: 2164-554X</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2024.2414546</identifier><identifier>PMID: 39411929</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Adult ; Aged ; Aged, 80 and over ; biomarker ; Biomarkers, Tumor - blood ; Female ; Gastric cancer ; Humans ; Hyponatremia - etiology ; immunotherapy ; Immunotherapy - Cancer ; Immunotherapy - methods ; Kaplan-Meier Estimate ; Male ; Middle Aged ; natrium ; Prognosis ; prognostic analysis ; Retrospective Studies ; Sodium - blood ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - mortality ; Stomach Neoplasms - pathology</subject><ispartof>Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2414546</ispartof><rights>2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024</rights><rights>2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c413t-4b61459c02b1b264935a791abca5de88687122c2b44fb3a0c8e9e05b060c54c63</cites><orcidid>0009-0008-7190-1515 ; 0009-0002-2553-4116</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2414546$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/21645515.2024.2414546$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>230,314,777,781,861,882,2096,27483,27905,27906,59122,59123</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39411929$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pan, Yuting</creatorcontrib><creatorcontrib>Ma, Yue</creatorcontrib><creatorcontrib>Guan, Huafang</creatorcontrib><creatorcontrib>Dai, Guanghai</creatorcontrib><title>Pre-treatment of hyponatremia as a biomarker for poor immune prognosis in advanced or metastatic gastric cancer: A retrospective case analysis</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>Hyponatremia, a prevalent electrolyte imbalance among tumor patients, has often been overlooked regarding its prognostic significance for immunotherapy. In this study, we delved into the prognostic ramifications of hyponatremia in advanced gastric cancer (AGC) patients undergoing immunotherapy. Enrolling AGC patients diagnosed between December 2014 and May 2021, we extracted pertinent data from electronic medical records, with a median follow-up of 35.8 months. Kaplan-Meier curves illuminated patients' progression-free survival (PFS) and overall survival (OS), while survival disparities were tested using the Mantel-Haenszel log rank test. COX and logistic regressions were employed to scrutinize the correlation between serum sodium levels and prognosis in 268 AGC patients, both at baseline and during treatment. Notably, patients with hyponatremia exhibited shorter PFS (4.7 vs 2.1 months, p = .001*) and OS (12.5 vs 3.9 months, p < .001*). Serum sodium emerged as an independent prognostic factor for both PFS (HR = 1.773; 95% CI 1.067-2.945; p = .001*) and OS (HR = 1.773; 95% CI 1.067-2.945; p = .003*). Subgroup analysis revealed that AGC patients with hyponatremia derived no benefit from immunotherapy in terms of PFS and OS. Strikingly, a decrease in serum sodium during immunotherapy was associated with early relapse and mortality. Based on these findings, we hypothesize that hyponatremia portends poor prognostic outcomes in AGC patients treated with immunotherapy and may serve as a valuable prognostic biomarker. However, further large-scale prospective studies are warranted to validate these observations.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>biomarker</subject><subject>Biomarkers, Tumor - blood</subject><subject>Female</subject><subject>Gastric cancer</subject><subject>Humans</subject><subject>Hyponatremia - etiology</subject><subject>immunotherapy</subject><subject>Immunotherapy - Cancer</subject><subject>Immunotherapy - methods</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>natrium</subject><subject>Prognosis</subject><subject>prognostic analysis</subject><subject>Retrospective Studies</subject><subject>Sodium - blood</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach Neoplasms - pathology</subject><issn>2164-5515</issn><issn>2164-554X</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9Uk1v1DAQjRCIVqU_AeQjl2xtx84HF6gqKJUqwQEkbtbEmWxdkjjY3q32T_CbmbDbFb3ggz2aefPmwy_LXgu-ErzmF1KUSmuhV5JLtZJKKK3KZ9np4s-1Vj-eH22hT7LzGO85nYrQZfkyOykaJUQjm9Ps99eAeQoIacQpMd-zu93sJyDX6IBBZMBa50cIPzGw3gc2e7rcOG4mZHPw68lHF5mbGHRbmCx2jOIjJogJkrNsTUag1y7B8I5dsoAp-DijTW6L5I_IYIJhRzyvshc9DBHPD-9Z9v3Tx29Xn_PbL9c3V5e3uVWiSLlqSxq5sVy2opWlagoNVSOgtaA7rOuyroSUVrZK9W0B3NbYINctL7nVypbFWXaz5-083Js5OBpwZzw489fhw9pAoO4HNKBlo23JRYdKSV3UnZWyURqVtIUFRVzv91zzph2xs7THAMMT0qeRyd2Ztd8aIVRNcwhieHtgCP7XBmMyo4sWhwEm9JtoCiEqXtVNXRBU76GWVhgD9sc6gptFG-ZRG2bRhjlog_Le_NvkMetRCQT4sAe4iX55hAcfhs4k2A0-9IH-zi19_LfGHwFByv0</recordid><startdate>20241231</startdate><enddate>20241231</enddate><creator>Pan, Yuting</creator><creator>Ma, Yue</creator><creator>Guan, Huafang</creator><creator>Dai, Guanghai</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0009-0008-7190-1515</orcidid><orcidid>https://orcid.org/0009-0002-2553-4116</orcidid></search><sort><creationdate>20241231</creationdate><title>Pre-treatment of hyponatremia as a biomarker for poor immune prognosis in advanced or metastatic gastric cancer: A retrospective case analysis</title><author>Pan, Yuting ; Ma, Yue ; Guan, Huafang ; Dai, Guanghai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-4b61459c02b1b264935a791abca5de88687122c2b44fb3a0c8e9e05b060c54c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>biomarker</topic><topic>Biomarkers, Tumor - blood</topic><topic>Female</topic><topic>Gastric cancer</topic><topic>Humans</topic><topic>Hyponatremia - etiology</topic><topic>immunotherapy</topic><topic>Immunotherapy - Cancer</topic><topic>Immunotherapy - methods</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>natrium</topic><topic>Prognosis</topic><topic>prognostic analysis</topic><topic>Retrospective Studies</topic><topic>Sodium - blood</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pan, Yuting</creatorcontrib><creatorcontrib>Ma, Yue</creatorcontrib><creatorcontrib>Guan, Huafang</creatorcontrib><creatorcontrib>Dai, Guanghai</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pan, Yuting</au><au>Ma, Yue</au><au>Guan, Huafang</au><au>Dai, Guanghai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pre-treatment of hyponatremia as a biomarker for poor immune prognosis in advanced or metastatic gastric cancer: A retrospective case analysis</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2024-12-31</date><risdate>2024</risdate><volume>20</volume><issue>1</issue><spage>2414546</spage><pages>2414546-</pages><issn>2164-5515</issn><issn>2164-554X</issn><eissn>2164-554X</eissn><abstract>Hyponatremia, a prevalent electrolyte imbalance among tumor patients, has often been overlooked regarding its prognostic significance for immunotherapy. In this study, we delved into the prognostic ramifications of hyponatremia in advanced gastric cancer (AGC) patients undergoing immunotherapy. Enrolling AGC patients diagnosed between December 2014 and May 2021, we extracted pertinent data from electronic medical records, with a median follow-up of 35.8 months. Kaplan-Meier curves illuminated patients' progression-free survival (PFS) and overall survival (OS), while survival disparities were tested using the Mantel-Haenszel log rank test. COX and logistic regressions were employed to scrutinize the correlation between serum sodium levels and prognosis in 268 AGC patients, both at baseline and during treatment. Notably, patients with hyponatremia exhibited shorter PFS (4.7 vs 2.1 months, p = .001*) and OS (12.5 vs 3.9 months, p < .001*). Serum sodium emerged as an independent prognostic factor for both PFS (HR = 1.773; 95% CI 1.067-2.945; p = .001*) and OS (HR = 1.773; 95% CI 1.067-2.945; p = .003*). Subgroup analysis revealed that AGC patients with hyponatremia derived no benefit from immunotherapy in terms of PFS and OS. Strikingly, a decrease in serum sodium during immunotherapy was associated with early relapse and mortality. Based on these findings, we hypothesize that hyponatremia portends poor prognostic outcomes in AGC patients treated with immunotherapy and may serve as a valuable prognostic biomarker. However, further large-scale prospective studies are warranted to validate these observations.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>39411929</pmid><doi>10.1080/21645515.2024.2414546</doi><orcidid>https://orcid.org/0009-0008-7190-1515</orcidid><orcidid>https://orcid.org/0009-0002-2553-4116</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2164-5515 |
| ispartof | Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2414546 |
| issn | 2164-5515 2164-554X 2164-554X |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_21645515_2024_2414546 |
| source | Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over biomarker Biomarkers, Tumor - blood Female Gastric cancer Humans Hyponatremia - etiology immunotherapy Immunotherapy - Cancer Immunotherapy - methods Kaplan-Meier Estimate Male Middle Aged natrium Prognosis prognostic analysis Retrospective Studies Sodium - blood Stomach Neoplasms - drug therapy Stomach Neoplasms - mortality Stomach Neoplasms - pathology |
| title | Pre-treatment of hyponatremia as a biomarker for poor immune prognosis in advanced or metastatic gastric cancer: A retrospective case analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T19%3A19%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pre-treatment%20of%20hyponatremia%20as%20a%20biomarker%20for%20poor%20immune%20prognosis%20in%20advanced%20or%20metastatic%20gastric%20cancer:%20A%20retrospective%20case%20analysis&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Pan,%20Yuting&rft.date=2024-12-31&rft.volume=20&rft.issue=1&rft.spage=2414546&rft.pages=2414546-&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2024.2414546&rft_dat=%3Cproquest_cross%3E3117078983%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3117078983&rft_id=info:pmid/39411929&rft_doaj_id=oai_doaj_org_article_a5295c601de442538dc22945e42c3ca4&rfr_iscdi=true |